International Journal of Endocrinology

International Journal of Endocrinology / 2014 / Article

Review Article | Open Access

Volume 2014 |Article ID 589587 |

Pawel Pludowski, William B. Grant, Harjit Pal Bhattoa, Milan Bayer, Vladyslav Povoroznyuk, Ema Rudenka, Heorhi Ramanau, Szabolcs Varbiro, Alena Rudenka, Elzbieta Karczmarewicz, Roman Lorenc, Justyna Czech-Kowalska, Jerzy Konstantynowicz, "Vitamin D Status in Central Europe", International Journal of Endocrinology, vol. 2014, Article ID 589587, 12 pages, 2014.

Vitamin D Status in Central Europe

Academic Editor: Ajai Kumar Srivastav
Received22 Jul 2013
Revised17 Feb 2014
Accepted26 Feb 2014
Published26 Mar 2014


Little published information is available regarding epidemiological data on vitamin D status in the large geographical region of Central Europe (CE). We searched the journal literature with regard to 25(OH)D concentrations among community-dwelling or healthy people living in CE. 25(OH)D concentrations varied by age, season, study sample size, and methodological approach [i.e., 25(OH)D assay used]. Concentrations of 25(OH)D in CE appeared lower than 30 ng/mL, and the magnitude of hypovitaminosis D was similar to that reported in Western Europe. While most of the studies reviewed were cross-sectional studies, a longitudinal study was also included to obtain information on seasonal variability. The longitudinal study reported wintertime 25(OH)D values close to 21–23 ng/mL for all studied age groups, with a significant increase of 25(OH)D in August reaching 42 ng/mL for those aged 0–9 years, but only 21 ng/mL for the elderly aged 80–89 years. The decrease in 25(OH)D with respect to age was attributed to decreased time spent in the sun and decreased vitamin D production efficiency. Based on the literature review on vitamin D status in the CE populations, it can be concluded that 25(OH)vitamin D levels are on average below the 30 ng/mL level.

1. Introduction

The literature published over the two last decades indicates increasing awareness of vitamin D’s pleiotropic, multidirectional action in the human body. Evidence from large-scale studies contributed to the understanding that vitamin D deficiency may be a significant risk factor for many civilization diseases. There is recognized benefit of vitamin D for bone health based on both observational studies and randomized controlled trials [1]. There is also evidence largely from cross-sectional, ecological, laboratory, and observational studies that vitamin D reduces risk of many types of cancer, cardiovascular disease, diabetes, autoimmune and metabolic disorders, infectious diseases linked to decreased immunity, and even some neuropsychiatric disorders [28]. Based on the journal literature for the nonskeletal effects of vitamin D, it appears that serum 25-hydroxyvitamin D [25(OH)D] concentrations between 30 and 50 ng/mL are associated with significantly reduced risk of such diseases [912]. Therefore, a variety of practical and research activities are being undertaken worldwide to evaluate vitamin D deficiency and improve vitamin D status. In Central Europe (CE), researchers representing the region developed recommendations to treat vitamin D deficiency for Poland in 2009 [13] and for Hungary in 2012 [14]. Because of convincing findings showing potential health benefits of vitamin D, investigators in CE focus on determining serum 25-hydroxyvitamin D [25(OH)D] concentrations in the general population and among different risk groups. This interest inspired a conference, “Vitamin D—minimum, maximum, optimum,” held in Warsaw, Poland, on October 19–20, 2012 ( The meeting was organized by the Children’s Memorial Health Institute, Department of Biochemistry, Radioimmunology, and Experimental Medicine, in Warsaw, with 550 attendees from European and non-European countries. The conference sought to establish recommendations on serum 25(OH)D concentrations for Central Europeans. A related goal was to develop an understanding of current serum 25(OH)D normative ranges and of how they vary with respect to such factors as age, sex, and season. The major purpose was to establish guidelines for appropriate vitamin D supplementation for Central Europeans of all ages in order to ensure adequate serum 25(OH)D concentration and, thereby, to guarantee short- and long-term effects, with appropriate safety considerations. The primary conclusion reached by the participants at the Warsaw conference was consensus on optimal (target) serum 25(OH)D concentrations ranging from 30 to 50 ng/mL (75–125 nmol/L). Although no convincing reports indicate adverse health effects of serum 25(OH)D concentrations up to 100 ng/mL (250 nmol/L), few studies show health benefits associated with levels higher than 50 ng/mL.

2. Materials and Methods

This paper reviews the available spectrum of data on serum 25(OH)D concentrations in CE, compared with selected findings from other European countries. We found several articles through advanced searches of the National Library of Medicine’s PubMed database and Scopus, using keywords “vitamin D” or “serum 25-hydroxyvitamin D” along with country names or “Europe.” Some of the CE “epidemiologic” studies reported at the vitamin D conference in Warsaw were also included for further analyses. Papers dealing with healthy or community-dwelling people were included in the tables, but people with diseases were not. However, one set of data for patients was given in a separate table because it provided longitudinal data on serum 25(OH)D concentrations throughout the year [15].

3. Results

Tables 14 provide explicit comparative information on serum 25(OH)D concentrations in Central European countries as a function of age [1646], whereas Table 5 gives information as a function of season (monthly intervals) stratified by age for a Hungarian population [15].

CountryCityLatitude, longitudeYearNumber, sexAgePopulation SeasonAssay, machine (manufacturer)Serum 25(OH)D (ng/mL)Reference

Czech RepublicPilzen49.8°N
April–June 200628NewbornTerm, cross sectionSpringCLIA, Liaison (DiaSorin)7 (6–13)[16]

31NewbornHealthyWinterRadiocompetitive, Extrelut column and radioassay7 ± 5[17]
22NewbornHealthySummer19 ± 10[17]

2001-200220 M
17 F
1 week
HealthyAnnual CLIA, Liaison (DiaSorin)15 ± 9[18]

3 weeks
HealthyAnnualCLIA, Liaison (DiaSorin)15 ± 9[19]

cord blood
HealthyWinterCLIA, Liaison (DiaSorin)14 ± 8[20]

cord blood
HealthySummerCLIA, Liaison (DiaSorin)24 ± 9[21]

15 M
15 F
2 weeksHealthyWinter, summerCLIA, Liaison (DiaSorin)8.5 (7–12)[22]

15 M
15 F
10 weeksHealthy, after supplementationWinter, summerCLIA, Liaison (DiaSorin)55 (35–67)[22]

Poland1346 monthsHealthy, after supplementationRIA43 ± 20[23]

Poland9812 monthsHealthy, after supplementationRIA29 ± 12[23]

YearNumber, sexAge (yrs)BMIPopulation SeasonAssay, machine (manufacturer)Serum 25(OH)D (ng/mL)Reference

2011-201247 M
33 F
11 (8–13)HealthyAutumn-winterECLIA, Cobas e411 (Roche Diagnostics)9 (5–15)[24]

100 M11–1420Healthy,
Cross section
Winter CLIA, IDS (IDS)23 ± 6 [25]
Hungary66 M11–1420HealthySummer41 ± 13
Hungary91 F11–1420HealthyWinter21 ± 8
Hungary53 F11–1420HealthySummer38 ± 14

199 F13 ± 1Community, cross sectionWinterHPLC12[26]

BMIPopulation SeasonAssay, machine (manufacturer)Serum 25(OH)D

BelarusWestern Belarus53°N
2010-20116 M
22 F
46 ± 727 ± 4HealthyAnnualECLIA, Elecsys (Roche Diagnostics)18 ± 7[28]

BelarusMinsk2011-2012168 F45–55HealthyAnnualECLIA, Cobas e411
(Roche Diagnostics)
29 ± 15[29]
BelarusMinsk176 F55–65Annual27 ± 14[29]

Czech RepublicPrague50.1°N
2004–20062175Clinic patientsAnnualRIA, IDS, UK31 ± 18[30]

Czech RepublicPilzen49.8°N
2008239 M
321 F
53 ± 1427 ± 5Community, cross sectionOct. 6–Nov. 28ECLIA, Cobas e411
(Roche Diagnostics)
25 ± 4[31]

2006167 M49 ± 1228 ± 5Community, cross section from patientsWinterRIA, DiaSorin17 ± 6[32]
Estonia200 F49 ± 1229 ± 7CommunityWinter18 ± 6[32]
Estonia167 M49 ± 1228 ± 5CommunitySummer24 ± 7[32]
Estonia200 F49 ± 1229 ± 7CommunitySummer23 ± 7[32]

HungaryCounty Vas47.2°N
201132 M<43 Healthy blood donors and others, cross sectionMarch–MayECLIA, Cobas e411
(Roche Diagnostics)
29 (25–40)[33]
HungaryCounty Vas48 F<43Healthy22 (29–40)[33]
HungaryCounty Vas36 M>43Healthy27 (22–34)[33]
HungaryCounty Vas21 F>43Healthy24 (16–34)[33]

31Mothers at deliveryWinterRadiocompetitive, Extrelut column and radioassay11 ± 7[17]
PolandWarsaw22Mothers at deliverySummer31 ± 15[17]

PolandKatowice 50.3°N 
2003-200417 F52 ± 424 ± 2HealthyAnnualRIA, Bio-Source Europe39 ± 18[34]

31 F47 (25–79)Healthy, employees of the Center of Oncology, OpoleNovember–MarchECLIA, (Roche Diagnostics)17[35]

PolandWarsaw76Mothers after deliveryHealthyWinterCLIA, Liaison    (DiaSorin)15 ± 8[20, 21]
PolandWarsaw40Mothers after deliveryHealthySummer20 ± 7[20, 21]
PolandWarsaw119Lactating womenHealthy Annual26 ± 7[20, 21]

PolandWarsaw138 FPregnant women
1st trimester
HealthyAnnual17.6 (4–57)[36]

PolandWarsaw138 FPregnant women
3rd trimester
HealthyAnnual18.5 (4–40)[36]

PolandWarsaw55Pregnant women
1st trimester
HealthyAnnual ECLIA, Elecsys 2010 (Roche Diagnostics)23 (17–57)[37]
PolandWarsaw55Pregnant women
2nd trimester
HealthyAnnual25 (6–53)[37]
PolandWarsaw55Pregnant women
3rd trimester
HealthyAnnual25 (3–50)[37]

2007162 F34HealthyOctoberHPLC33 ± 13[38]

Ukraine 44.2°N–52.2°N2010-2011649 F47 (20–59)28 ± 6HealthyAnnualECLIA, Elecsys 2010 (Roche Diagnostics)14 ± 9[39, 40]
Ukraine2010-2011129 M44 (20–59)26 ± 6HealthyAnnual15 ± 10[39, 40]
Ukraine2010-2011102 F
28 M
47 ± 1027 ± 5HealthyWinter13 ± 8[39, 40]
Ukraine2010-2011160 F
37 M
45 ± 1127 ± 5HealthySummer18 ± 10[39, 40]

CountryCityLatitude, longitudeYearNumber, sexAge (yrs)BMIPopulation SeasonAssay, machine (manufacturer)Serum 25(OH)D (ng/mL)Reference

Belarus178 F65–75AnnualECLIA, Cobas e411 (Roche Diagnostics)26 ± 14[29]
Belarus101 F>75Annual19 ± 9[29]

319 F65 (41–91)26 ± 4CommunityYear RIA, DiaSorin19 (5–54)[43]
HungaryDebrecen100 F65CommunitySpring17 (5–40)[43]
HungaryDebrecen80 F65CommunitySummer20 (5–41)[43]
HungaryDebrecen79 F65CommunityAutumn21 (5–54)[43]
HungaryDebrecen60 F65CommunityWinter20 (5–41)[43]

September 2009–September 2010206 M60 (51–81)29 (17–42)HealthyYearHPLC29 (4–74)[44]

HungaryDebrecen59 M6028CommunitySpring   HPLC27 (4–66)[44]
HungaryDebrecen96 M6130CommunitySummer33 (7–74)[44]
HungaryDebrecen24 M6129CommunityAutumn25 (6–58)[44]
HungaryDebrecen30 M5929CommunityWinter23 (5–45)[44]

Poland65 F72 ± 1HealthyWinterHPLC13[26]

Ukraine149 F6529 ± 5Healthy, not treated with vitamin D, cross sectionWinterCLIA, Liaison (DiaSorin) and ECLIA, Elecsys 2010 (Roche Diagnostics)13 ± 7[39, 40]
Ukraine124 F7530 ± 4Healthy, Winter14 ± 8[39, 40]
2010-2011711 F69 (60–95)29 ± 5HealthyAnnual13 ± 8[39, 40]
Ukraine2010-201186 M71 (60–91)28 ± 4HealthyAnnual16 ± 9[39, 40]
Ukraine2010-2011120 F
69 ± 630 ± 6HealthyWinter
11 ± 6[39, 40]
Ukraine2010-2011305 F68 ± 628 ± 5HealthySummer15 ± 8 [39, 40]

Month0–9 years10–1920–2930–3940–4950–5960–6970–7980–89SDD


3.1. Neonates and Infants

Eight studies in this review reported serum 25(OH)D concentrations for neonates and infants in CE: one from the Czech Republic and seven from Poland (Table 1). Mean serum 25(OH)D concentration among neonates ranged between 7 and 24 ng/mL depending on season. Winter and spring values were low, 7–14 ng/mL, whereas summertime values were better (19–24 ng/mL). Recent Polish studies confirmed the above observations, showing higher summertime than winter/spring mean 25(OH)D concentrations in the umbilical cord: 24.0 ± 8.5 ng/mL versus 13.5 ± 8.2 ng/mL (), respectively [2022]. Serum 25(OH)D values found in these studies appeared lower than those recommended on the basis of a recent randomized controlled trial of vitamin D supplementation during pregnancy. This study, performed by Hollis and colleagues, demonstrated association between the 25(OH)D level of 40 ng/mL and optimal serum 1,25-dihydroxyvitamin D concentrations [47]. Fortunately, implementing recommendations for neonates to start vitamin D supplementation from the first days after delivery resolved, at least partly, vitamin D deficiency during the first few months of life. As Czech-Kowalska and colleagues showed, supplementing neonates with daily doses of ~550 IU of vitamin D increased serum 25(OH)D to 55 ng/mL at the third month of life [22]. Further, in the group of infants () regularly supplemented with a vitamin D dose of ~1160 IU/day at both the 6th and 12th month, 25(OH)D serum concentrations unexpectedly decreased from 40.2 ± 18.8 ng/mL at the 6th month to 32.0 ± 12.7 ng/mL at the 12th month () [17]. However, reduced daily vitamin D intake expressed in international units/kilogram of body weight may account for the observed decrease in 25(OH)D concentration [23].

3.2. Children and Adolescents

Table 2 shows serum 25(OH)D concentrations in children and adolescents. In Central European countries, wintertime values ranged from 9 ng/mL in Belarus [24] to 23 ng/mL in Hungary [25]; summertime values ranged from 36 to 56 ng/mL. The large winter range may be due to different 25(OH)D assays used, which will be discussed later. In addition, studies with smaller sample size may have been associated with variations in 25(OH)D concentrations due to recruiting people who may not have been representative of the larger population.

3.3. Adults

Table 3 presents serum 25(OH)D concentrations for adults aged 20–60 years. In CE, wintertime 25(OH)D concentrations ranged from 11 ng/mL in Poland to 18 ng/mL in Estonia. Summertime 25(OH)D concentrations ranged from 18 ng/mL in Ukraine to 35 ng/mL in Hungary, and annual values found in larger studies (>100 cases) ranged from 14 ng/mL in Ukraine to 29 ng/mL in Belarus. In Western European countries of similar latitude, wintertime values ranged from 13 ng/mL in Denmark to 20 ng/mL in Austria, whereas those in summertime ranged from 23 to 35 ng/mL, and annual values were reported as 25 ng/mL in France [41]. Thus, 25(OH)D serum concentrations of Central European and Western European countries showed consistent agreement. Some information is available in the studies regarding serum 25(OH)D concentrations in men and women. A study from Great Britain involving 45-year olds in a cohort study found that women had statistically higher concentrations than men in winter, while men had statistically higher concentrations in summer [42]. The differences might be due to men spending more time outdoors and women taking more oral vitamin D. A study from Estonia found similar but statistically nonsignificant results: in summer, men had a mean serum 25(OH)D concentration of 24.2 ng/mL while women had 23.4 ng/mL, while in winter the values for males and females were 17.1 ng/mL and 17.8 ng/mL, respectively [32].

3.4. The Elderly

Table 4 gives serum 25(OH)D concentrations for seniors aged 60 years or older. In Central European countries, wintertime 25(OH)D concentrations ranged from 11 ng/mL in Ukraine to 20 ng/mL in Hungary. Summertime 25(OH)D concentrations ranged from 15 ng/mL in Ukraine to 33 ng/mL in Hungary. Annual 25(OH)D concentrations ranged from 13 ng/mL in Ukraine to 29 ng/mL in Hungary. In Western European countries, wintertime values ranged from 17 to 20 ng/mL. Analyzing serum 25(OH)D concentrations with respect to latitude in either Central or Western European countries revealed no consistent variability. At least in part, the reasons for this could include that the solar ultraviolet-B (UVB) dose gradient during European summer is not large above 40°N latitude and that skin pigmentation becomes lighter as latitude increases, making it easier to generate vitamin D from solar UVB [48]. As noted in Table 5, serum 25(OH)D concentrations decrease with age above about 50 years. Since most studies summarized in this table reported 25(OH)D concentrations for a limited range of ages, stated in the table, the values in the table should be considered representative of those for the age ranges studied and not for those over the age of 60 years.

3.5. Effect of Age and Season

A useful study on the variation of serum 25(OH)D3 concentration with respect to age in 10-year groupings and month of measurement (Table 5) was reported for a population from Budapest, Hungary (47.5°N latitude, 16.8°E longitude) [15]. Although the subjects studied were patients, nothing indicated that their morbidity affected serum 25(OH)D3 concentration. However, the report noted that, for the 1307 subjects with repeated measurements, serum 25(OH)D concentrations were lower for the second measurement (26 ± 9 ng/mL) than for the first (27 ± 13 ng/mL), suggesting that the medical staff did not recommended taking vitamin D supplements. Table 5 gives a summary of data from that study. Several months were omitted for which serum 25(OH)D3 concentrations either did not change or were inconsistent with concentrations for other months; values in January were similar to those in May. Several associations become clear from the content of Table 5: serum 25(OH)D3 concentration increased minimally before June except for the population aged 0–9 years. For all ages, serum 25(OH)D3 concentration started to decline in September and reached wintertime values by October. Peak serum 25(OH)D3 concentrations were the highest for the youngest people and the lowest for the oldest people. The wintertime mean serum 25(OH)D concentration was about 20–23 ng/mL for all ages. The increase in summer amounted to 20 ng/mL for those aged 0–9 years, 14–15 ng/mL for those aged 10–49 years, 10 ng/mL for those aged 50–69 years, and 5–6 ng/mL for those aged 70–89 years. Two primary factors accounted for age-related seasonal fluctuations (i.e., differences in summertime peak values): limited time spent outdoors in sunlight and reduced efficiency of vitamin D production from UVB irradiance. In a mid-1980s study, vitamin D production efficiency reported for people older than 60 years was about 25% of that for those younger than 20 years [49], owing to less 7-dehydrocholesterol in the skin, which is converted to vitamin D3 through the action of UVB irradiance followed by a thermal process. The change in vitamin D production in summer as a function of age agrees with the efficiency study. Those with darker skin make vitamin D more slowly than those with light skin since the melanin in the skin reduces the transmission of solar UVB to the 7-dehydrocholesterol. In addition, Table 5 gives calculated standard vitamin D doses (SDD) for whole-day irradiance for solar UVB measured in Belsk, Poland (52°N latitude, 21°E longitude) [50]. However, because vitamin D3 production is limited to 10 000–20 000 IU/day (since UV both produces vitamin D and destroys its metabolites), one cannot use the SDD values to estimate vitamin D production for a given time in the sun. For such information, the graphs in the papers by Webb and Engelsen [51] and Bakos and Mikó [52] are useful. Vitamin D production potential peaks near the end of June, whereas serum 25(OH)D3 concentration peaks in August. The lag of about 6 weeks is related primarily to the time required to build up serum 25(OH)D concentration. Serum 25(OH)D is the most important clinically available measurement of vitamin D status, reflecting lifestyle and dietary habits [53]. Determining the amount provided by the sun or food is difficult. The duration and intensity of exposure to sunlight are not easily measurable, and age, skin pigmentation, sunscreens, clothing, and even window glass reduce its effects [54]. In equatorial regions exposure to the sun alone is adequate, but at latitudes above 40 degrees north or south and higher, people make little vitamin D in the winter. Measurement of serum 25(OH)D provides direct information. Although its concentration depends on vitamin D production and intake, its serum half-life is much longer than that of vitamin D (weeks versus hours), and it therefore provides an integrated assessment of vitamin D status. Serum 25(OH)D concentrations depend on age, sunlight exposure, vitamin D dietary intake, or supplementation.

3.6. 25(OH)D Assays Used

The spectrum of methods commonly used in research and laboratory practice includes three types: manual immunoassays, automated immunoassays, and direct detection methods. Most instruments or approaches yield reasonably accurate measurements; however, some instruments appear problematic [44]. Several reports have also discussed analogous pitfalls of the assays [5559]. In a comparison of 25(OH)D assays in Sweden, a high-pressure liquid chromatography (HPLC) assay measured 34 ± 2 ng/mL, a radioimmunoassay (RIA) measured 28 ± 2 ng/mL, and a competitive immunochemiluminescence assay (CILA) measured 24 ± 2 ng/mL [56]. In a comparison of assays with liquid chromatography-tandem mass spectrometry methods in Australia, DiaSorin LIAISON, IDS, and Siemens assays met minimum performance goals [59]. In a comparison study in Warsaw, the Elecsys (total vitamin D) from Roche measured about 2 ng/mL higher than the LIAISON from DiaSorin [60]. Immunoassays are sensitive to 24,25-dihydroxyvitamin D, which can occur at concentrations up to 5 ng/mL [61]. Vitamin D-binding protein concentrations also affect the accuracy of serum 25(OH)D concentration measurement [62]. Some laboratories validated their assay performance by comparing measurements with samples submitted to the international Vitamin D External Quality Assessment Scheme (DEQAS) [58]. Comparability of 25(OH)D results could be facilitated if all laboratories were to participate with DEQAS.

4. Discussion

To our knowledge, this study is the first to summarize available data regarding vitamin D status and epidemiology in Central European populations of different ages. Most populations and most age groups have at least a moderate deficit of 25(OH)D according to currently binding standard references. The potential limitation we acknowledge is that all studies in this review are either retrospective or cross-sectional. To draw firm conclusions on intraindividual variations in 25(OH)D levels in different seasons, a prospective study design would be desirable. With the exception of two studies [43, 44], no particular inclusion or exclusion criteria for study participation were assumptive; therefore, we recognize that studied populations may have been heterogeneous. Furthermore, 25(OH)D3 and total 25(OH)D concentrations were usually similar but not identical, so we analyzed results from studies irrespective of type of vitamin D determination. A review of 394 studies of unadjusted serum 25(OH)D concentrations from around the world found a mean value of 22 ± 1 ng/mL, with no effect of latitude for nonwhites [63]. However, the regression fit to the data for white people went from approximately 40 ng/mL near the equator to approximately 16 ng/mL at the poles. What happens in Europe is still not clear from that paper. Evidently, skin pigmentation (as well as diet at high latitudes) have adapted well to solar UVB doses where people have lived for millennia [48]. A review of serum 25(OH)D concentrations among dark-skinned people living in Europe—primarily those of African, Asian, or Middle Eastern origin—supports this hypothesis. These ethnically different groups had lower serum 25(OH)D concentrations than the indigenous white inhabitants [64]. The three important factors contributing to the difference were darker skin, clothing that covered more skin area, and limited oral vitamin D intake from food. Serum 25(OH)D concentrations in winter do not drop as low as might be expected on the basis of solar UVB doses in winter for two reasons: (1) the decay time of 25(OH)D is 4–6 weeks—that is, the time it takes to drop to half its value—and (2) when serum 25(OH)D concentrations are low, the body converts vitamin D to 25(OH)D much more efficiently [65].

The following question emerges: if the natural sources of vitamin D that arrived at over millennia lead to mean annual serum 25(OH)D concentrations slightly above 20 ng/mL, why is this value not adequate? One point to be addressed is that life expectancy has considerably increased in Europe and elsewhere during the past century because of health care advances that reduced the risk of dying from accidents, digestive diseases, and respiratory and other infections [66]. Europeans are therefore much more likely to die now from cancer or cardiovascular disease. Ecological and observational studies offer moderate evidence that vitamin D reduces the risk of cancer [6769] and cardiovascular disease [70]. Thus, raising serum 25(OH)D concentrations above 30–40 ng/mL should reduce mortality rates by about 15% and increase life expectancy by 2 years in Europe [71]. Although the above associations may be regarded cautiously and require further long-term prospective investigation, it is rather justified to recommend an individualized vitamin D supplementation to all age groups in CE. The practical approach of such a strategy is aimed to alleviate the vitamin D status in this region—that is, to consequently diminish the risk of 25(OH)D deficits.

5. Summary and Conclusion

The essential finding in this review is that most people living in both Central and Western Europe have serum 25(OH)D concentrations below the optimal values of 30–50 ng/mL. The main reason is that solar UVB, being the primary source of vitamin D, is limited for most CE populations; thus, producing vitamin D from solar UVB from October through March is nearly impossible above 40°N latitude. By consequence, the concentrations are particularly low from October through May, implicating the deficiency to a large extent [15]. Also, most people spend most time indoors and so they produce vitamin D only through casual sunlight exposure, which raises mean serum 25(OH)D concentration from 15 ng/mL in February to 30 ng/mL in September for individuals aged 45 years living in the UK [42]. The groups at particularly high risk of vitamin D deficiency include those largely staying indoors, pregnant and nursing women, newborns, breast-fed infants without vitamin D supplementation, overweight or obese people [72], patients with chronic or infectious disease, and those older than 50 years. A variety of preventive means and interventions can be implemented in CE to increase serum 25(OH)D concentrations, including increased but reasonable solar UVB irradiance, fortification of food, and augmented consumption of vitamin D supplements.

Conflict of Interests

William B. Grant receives funding from Bio-Tech Pharmacal (Fayetteville, AR) and the Sunlight Research Forum (Veldhoven) and has received funding from the UV Foundation (McLean, VA), the Vitamin D Council (San Luis Obispo, CA), and the Vitamin D Society (Canada). Other authors declare that there is no conflict of interests regarding the publication of this paper.


This work was supported in part by the Polish Grant of MNiSW 5412/B/P01/2010/39 and EU Structural Grant no. POIG.02.01.00-14-059/09.


  1. A. C. Ross, J. E. Manson, S. A. Abrams et al., “The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 1, pp. 53–58, 2011. View at: Publisher Site | Google Scholar
  2. W. B. Grant, “Ecological studies of the UVB-vitamin D-cancer hypothesis,” Anticancer Research, vol. 32, no. 1, pp. 223–236, 2012. View at: Google Scholar
  3. P. Pludowski, M. F. Holick, S. Pilz et al., “Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality—a review of recent evidence,” Autoimmunity Reviews, vol. 12, no. 10, pp. 976–989, 2013. View at: Publisher Site | Google Scholar
  4. P. Pludowski, E. Karczmarewicz, M. Bayer et al., “Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe—recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency,” Endokrynologia Polska, vol. 64, no. 4, pp. 319–327, 2013. View at: Google Scholar
  5. C. Palacios and L. Gonzalez, “Is vitamin D deficiency a major global public health problem?” The Journal of Steroid Biochemistry and Molecular Biology, 2013. View at: Publisher Site | Google Scholar
  6. J. L. Anderson, H. T. May, B. D. Horne et al., “Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population,” The American Journal of Cardiology, vol. 106, no. 7, pp. 963–968, 2010. View at: Publisher Site | Google Scholar
  7. J. R. Sabetta, P. DePetrillo, R. J. Cipriani, J. Smardin, L. A. Burns, and M. L. Landry, “Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults,” PLoS ONE, vol. 5, no. 6, p. e11088, 2010. View at: Publisher Site | Google Scholar
  8. L. R. Harms, T. H. J. Burne, D. W. Eyles, and J. J. McGrath, “Vitamin D and the brain,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 25, no. 4, pp. 657–669, 2011. View at: Publisher Site | Google Scholar
  9. A. Hossein-Nezhad and M. F. Holick, “Vitamin D for health: a global perspective,” Mayo Clinic Proceedings, vol. 88, no. 7, pp. 720–755, 2013. View at: Publisher Site | Google Scholar
  10. M. F. Holick, N. C. Binkley, H. A. Bischoff-Ferrari et al., “Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 7, pp. 1911–1930, 2011. View at: Publisher Site | Google Scholar
  11. M. F. Holick, N. C. Binkley, H. A. Bischoff-Ferrari et al., “Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 4, pp. 1153–1158, 2012. View at: Publisher Site | Google Scholar
  12. A. Valcour, F. Blocki, D. M. Hawkins, and S. D. Rao, “Effects of age and serum 25-OH-vitamin D on serum parathyroid hormone levels,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 11, pp. 3989–3995, 2012. View at: Publisher Site | Google Scholar
  13. J. Charzewska, D. Chlebna-Sokół, A. Chybicka et al., “Recommendations of prophylaxis of vitamin D deficiency in Poland (2009),” Medycyna Wieku Rozwojowego, vol. 14, no. 2, pp. 218–223, 2010. View at: Google Scholar
  14. I. Takács, I. Benkő, E. Toldy et al., “Hungarian consensus regarding the role of vitamin D in the prevention and treatment of diseases,” Orvosi Hetilap, vol. 153, pp. S5–S26, 2012. View at: Google Scholar
  15. B. Vásárhelyi, A. Sátori, F. Olajos, A. Szabó, and G. Beko, “Low vitamin D levels among patients at Semmelweis University: retrospective analysis during a one-year period,” Orvosi Hetilap, vol. 152, no. 32, pp. 1272–1277, 2011. View at: Publisher Site | Google Scholar
  16. J. Dort, M. Bayer, E. Dortová, and V. Hadravová, “Vitamin D and other parameters of calcium and phosphate metabolism in healthy term newborns after birth,” Osteologicky Bulletin, vol. 12, no. 2, pp. 70–73, 2007. View at: Google Scholar
  17. A. Pluta, A. Karwacki, and K. Prószyńska, “Vitamin D status of mothers and newborns in relation to the season of a year,” Polski Tygodnik Lekarski, vol. 42, pp. 254–256, 1987. View at: Google Scholar
  18. J. Czech-Kowalska and A. Dobrzanska, “Vitamin D status in term newborn infants,” Kliniczna Perinatologia i Ginekologia, vol. 36, pp. 41–46, 2002. View at: Google Scholar
  19. J. Czech-Kowalska, A. Dobrzanska, J. Janowska et al., “Neonatal vitamin D status and calcium-phosphorus homeostasis in the third week of life,” Medycyna Wieku Rozwojowego, vol. 8, no. 1, pp. 115–124, 2004. View at: Google Scholar
  20. J. Czech-Kowalska, E. Kryskiewicz, M. Jaworski et al., “Mothers and newborns vitamin D status and bone mass according to season—preliminary results,” Acta Médica Portuguesa, vol. 25, supplement 2, article 151, 2012. View at: Google Scholar
  21. J. Czech-Kowalska, J. Latka-Grot, D. Bulsiewicz et al., “Maternal vitamin D supplementation during lactation—influence on maternal and offspring vitamin D status—randomised control trial—preliminary results,” Standardy Medyczne Pediatria, vol. 9, no. 5, article 730, 2012. View at: Google Scholar
  22. J. Czech-Kowalska, P. Pludowski, A. Dobrzanska et al., “Impact of vitamin D supplementation on markers of bone mineral metabolism in term infants,” Bone, vol. 51, no. 4, pp. 781–786, 2012. View at: Publisher Site | Google Scholar
  23. P. Pludowski, P. Socha, E. Karczmarewicz et al., “Vitamin D supplementation and status in infants: a prospective cohort observational study,” Journal of Pediatric Gastroenterology and Nutrition, vol. 53, no. 1, pp. 93–99, 2011. View at: Publisher Site | Google Scholar
  24. A. S. Pachkaila, E. V. Rudenka, and H. Zhernosek, “Vitamin D status in healthy Belarusian children in accordance with the blood levels of 25-hydroxyvitamin D3 and total 25-hydroxyvitamin D,” Standardy Medyczne, vol. 9, no. 5, article 743, 2012. View at: Google Scholar
  25. M. Antal, A. Regöly-Mérei, L. Biró et al., “Nutrition, life-style practice, serum vitamin D concentration and bone density in Hungarian adolescents,” Acta Alimentaria, vol. 35, no. 1, pp. 53–61, 2006. View at: Publisher Site | Google Scholar
  26. R. Andersen, C. Mølgaard, L. T. Skovgaard et al., “Teenage girls and elderly women living in northern Europe have low winter vitamin D status,” European Journal of Clinical Nutrition, vol. 59, pp. 533–541, 2005. View at: Publisher Site | Google Scholar
  27. T. R. Hill, A. A. Cotter, S. Mitchell et al., “Vitamin D status and its determinants in adolescents from the Northern Ireland Young Hearts 2000 cohort,” British Journal of Nutrition, vol. 99, no. 5, pp. 1061–1067, 2008. View at: Publisher Site | Google Scholar
  28. V. A. Snezhitskiy, L. V. Yankovskaya, V. V. Povorozniuk et al., “Vitamin D deficiency/insufficiency among residents of the western region of Belarus suffering from cardiovascular pathology,” Standardy Medyczne Pediatria, vol. 9, pp. 577–582, 2012. View at: Google Scholar
  29. E. Rudenka, “Vitamin D status among adults living in a Republic of Belarus,” in Proceedings of the “Vitamin D-Minimum, Maximum, Otimum” Conference, Warsaw, Poland, October 2012. View at: Google Scholar
  30. M. Vosatkova, P. Hoskovcova, and R. Bílek, “Vitamin D and its metabolites—supply of patients with various endocrine disorders and comparison of analytical methods,” Endocrine Regulations, vol. 41, no. 1, pp. 19–28, 2007. View at: Google Scholar
  31. O. Mayer Jr., J. Filipovský, J. Seidlerová et al., “The association between low 25-hydroxyvitamin D and increased aortic stiffness,” Journal of Human Hypertension, vol. 26, no. 11, pp. 650–655, 2012. View at: Publisher Site | Google Scholar
  32. M. Kull Jr., R. Kallikorm, A. Tamm, and M. Lember, “Seasonal variance of 25-(OH) vitamin D in the general population of Estonia, a Northern European country,” BMC Public Health, vol. 9, article 22, 2009. View at: Publisher Site | Google Scholar
  33. E. Virágh, D. Horváth, Z. Lőcsei et al., “Vitamin D supply among healthy blood donors in County Vas, Hungary,” Orvosi Hetilap, vol. 153, no. 41, pp. 1629–1637, 2012. View at: Publisher Site | Google Scholar
  34. M. Holecki, B. Zahorska-Markiewicz, J. Chudek, and A. Wiȩcek, “Changes in bone mineral density and bone turnover markers in obese women after short-term weight loss therapy during a 5-year follow-up,” Polskie Archiwum Medycyny Wewnetrznej, vol. 120, no. 7-8, pp. 248–254, 2010. View at: Google Scholar
  35. A. Pardej, K. Czerw, M. Gryboś, and W. Guzikowski, “Blood serum hydroxyvitamin D concentration in ovarian cancer,” Ginekologia i Poloznictwo, vol. 22, no. 4, pp. 63–68, 2011. View at: Google Scholar
  36. T. Laskowska-Klita, M. Chełchowska, J. Ambroszkiewicz, P. Kubik, and J. Leibschang, “The effect of vitamin-mineral supplementation on vitamins D, A (beta-carotene) and E concentration in blood of matched maternal-cord pairs,” Przegļd lekarski, vol. 61, no. 7, pp. 755–759, 2004. View at: Google Scholar
  37. Z. Bartoszewicz, A. Kondracka, M. Krasnodebska, B. Niedzwiedzka, and T. Bednarczuk, “Vitamin D deficiency In pregnant women from Warsaw,” Standardy Medyczne, vol. 9, no. 5, article 738, 2012. View at: Google Scholar
  38. P. Masaryk, A. Letkovská, A. Stecová et al., “Prevalence of vitamin D in population of healthy premenopausal women of Slovakia with normal bone mineral density,” Rheumatologia, vol. 24, no. 2, pp. 39–43, 2010. View at: Google Scholar
  39. V. V. Povoroznyuk, N. I. Balatska, F. Klymovytsky, O. Synenky, and V. Vayda, “Frequency of vitamin D deficiency amount Ukrainian population,” Journal of Musculoskeletal and Neuronal Interactions, vol. 12, no. 2, article 109, 2012. View at: Google Scholar
  40. V. V. Povoroznyuk and N. I. Balatska, “Vitamin D deficiency and insufficiency among Ukrainian population: age and gender peculiarities,” Problem of Osteology, vol. 3, pp. 3–6, 2012. View at: Google Scholar
  41. P. Engel, G. Fagherazzi, A. Boutten et al., “Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 9, pp. 2341–2350, 2010. View at: Publisher Site | Google Scholar
  42. E. Hyppönen and C. Power, “Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors,” The American Journal of Clinical Nutrition, vol. 85, no. 3, pp. 860–868, 2007. View at: Google Scholar
  43. H. P. Bhattoa, P. Bettembuk, S. Ganacharya, and A. Balogh, “Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in community dwelling postmenopausal Hungarian women,” Osteoporosis International, vol. 15, no. 6, pp. 447–451, 2004. View at: Google Scholar
  44. H. P. Bhattoa, E. Nagy, C. More et al., “Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in healthy Hungarian men over 50 years of age: the HunMen Study,” Osteoporosis International, vol. 24, no. 1, pp. 179–186, 2013. View at: Publisher Site | Google Scholar
  45. L. Napiórkowska, T. Budlewski, W. Jakubas-Kwiatkowska, V. Hamzy, D. Gozdowski, and E. Franek, “Prevalence of low serum vitamin D concentration in an urban population of elderly women in Poland,” Polskie Archiwum Medycyny Wewnetrznej, vol. 119, no. 11, pp. 699–703, 2009. View at: Google Scholar
  46. D. Durup, H. L. Jørgensen, J. Christensen, P. Schwarz, A. M. Heegaard, and B. Lind, “A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice, the CopD Study,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 8, pp. 2644–2652, 2012. View at: Publisher Site | Google Scholar
  47. B. W. Hollis, D. Johnson, T. C. Hulsey, M. Ebeling, and C. L. Wagner, “Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness,” Journal of Bone and Mineral Research, vol. 26, no. 10, pp. 2341–2357, 2011. View at: Publisher Site | Google Scholar
  48. N. G. Jablonski and G. Chaplin, “Human skin pigmentation as an adaptation to UV radiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 2, pp. 8962–8968, 2010. View at: Publisher Site | Google Scholar
  49. J. MacLaughlin and M. F. Holick, “Aging decreases the capacity of human skin to produce vitamin D3,” Journal of Clinical Investigation, vol. 76, no. 4, pp. 1536–1538, 1985. View at: Google Scholar
  50. J. W. Krzyścin, J. Jarosławski, and P. S. Sobolewski, “A mathematical model for seasonal variability of vitamin D due to solar radiation,” Journal of Photochemistry and Photobiology B: Biology, vol. 105, no. 1, pp. 106–112, 2011. View at: Publisher Site | Google Scholar
  51. A. R. Webb and O. Engelsen, “Calculated ultraviolet exposure levels for a healthy vitamin D status,” Photochemistry and Photobiology, vol. 82, no. 6, pp. 1697–1703, 2006. View at: Publisher Site | Google Scholar
  52. J. Bakos and P. Mikó, “Vitamin D forming effectivenss of ultraviolet radiation from sunlight in different months in Budapest, Hungary,” Orvosi Hetilap, vol. 148, no. 7, pp. 319–325, 2007. View at: Publisher Site | Google Scholar
  53. S. J. Silverberg, L. A. Fitzpatrick, and J. P. Bilezikian, “The role of parathyroid hormone and vitamin D in the pathogenesis of osteoporosis,” in Osteoporosis, R. Marcus, D. Feldman, and J. Kesley, Eds., pp. 716–726, Academic Press, San Diego, Calif, USA, 1996. View at: Google Scholar
  54. M. F. Holick, “McCollum award lecture, 1994: vitamin D—new horizons for the 21st century,” The American Journal of Clinical Nutrition, vol. 60, no. 4, pp. 619–630, 1994. View at: Google Scholar
  55. B. W. Hollis and R. L. Horst, “The assessment of circulating 25(OH)D and 1,25(OH)2D: where we are and where we are going,” Journal of Steroid Biochemistry and Molecular Biology, vol. 103, no. 3–5, pp. 473–476, 2007. View at: Publisher Site | Google Scholar
  56. N. Binkley, D. Krueger, and G. Lensmeyer, “25-hydroxyvitamin D measurement, 2009: a review for clinicians,” Journal of Clinical Densitometry, vol. 12, no. 4, pp. 417–427, 2009. View at: Publisher Site | Google Scholar
  57. G. Snellman, H. Melhus, R. Gedeborg et al., “Determining vitamin D status: a comparison between commercially available assays,” PLoS ONE, vol. 5, no. 7, Article ID e11555, 2010. View at: Publisher Site | Google Scholar
  58. G. D. Carter, “25-hydroxyvitamin D: a difficult analyte,” Clinical Chemistry, vol. 58, no. 3, pp. 486–488, 2012. View at: Publisher Site | Google Scholar
  59. C. J. L. Farrell, S. Martin, B. McWhinney, I. Straub, P. Williams, and M. Herrmann, “State-of-the-art vitamin D assays: a comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods,” Clinical Chemistry, vol. 58, no. 3, pp. 531–542, 2012. View at: Publisher Site | Google Scholar
  60. E. Karczmarewicz, E. Kryskiewicz, E. Skorupa, and P. Pludowski, “Comparison of two automated serum 25(OH)D assays—experience of pediatric hospital laboratory participating in DEQAS proficiency testing,” Postepy Nauk Medycznych, vol. 25, no. 3, pp. 193–199, 2011. View at: Google Scholar
  61. R. D. Coldwell, D. J. H. Trafford, and H. L. J. Makin, “Specific estimation of 24,25-dihydroxyvitamin D in plasma by gas chromatography-mass spectrometry,” Clinical Chemistry, vol. 30, no. 7, pp. 1193–1198, 1984. View at: Google Scholar
  62. A. C. Heijboer, M. A. Blankenstein, I. P. Kema, and M. M. Buijs, “Accuracy of 6 routine 25-hydroxyvitamin D assays: influence of vitamin D binding protein concentration,” Clinical Chemistry, vol. 58, no. 3, pp. 543–548, 2012. View at: Publisher Site | Google Scholar
  63. T. Hagenau, R. Vest, T. N. Gissel et al., “Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis,” Osteoporosis International, vol. 20, no. 1, pp. 133–140, 2009. View at: Publisher Site | Google Scholar
  64. I. M. van der Meer, B. J. C. Middelkoop, A. J. P. Boeke, and P. Lips, “Prevalence of vitamin D deficiency among Turkish, Moroccan, Indian and sub-Sahara African populations in Europe and their countries of origin: an overview,” Osteoporosis International, vol. 22, no. 4, pp. 1009–1021, 2011. View at: Publisher Site | Google Scholar
  65. C. F. Garland, C. B. French, L. L. Baggerly, and R. P. Heaney, “Vitamin D supplement doses and serum 25-Hydroxyvitamin D in the range associated with cancer prevention,” Anticancer Research, vol. 31, no. 2, pp. 617–622, 2011. View at: Google Scholar
  66. S. de Flora, A. Quaglia, C. Bennicelli, and M. Vercelli, “The epidemiological revolution of the 20th century,” FASEB Journal, vol. 19, no. 8, pp. 892–897, 2005. View at: Publisher Site | Google Scholar
  67. C. F. Garland, E. D. Gorham, S. B. Mohr, and F. C. Garland, “Vitamin D for cancer prevention: global perspective,” Annals of Epidemiology, vol. 19, no. 7, pp. 468–483, 2009. View at: Publisher Site | Google Scholar
  68. W. B. Grant, “How strong is the evidence that solar ultraviolet B and vitamin D reduce the risk of cancer? An examination using Hill’s criteria for causality,” Dermato-Endocrinology, vol. 1, pp. 17–24, 2009. View at: Publisher Site | Google Scholar
  69. M. Moukayed and W. B. Grant, “Molecular link between vitamin D and cancer prevention,” Nutrients, vol. 5, no. 10, pp. 3993–4023, 2013. View at: Google Scholar
  70. L. Wang, Y. Song, J. E. Manson et al., “Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies,” Circulation: Cardiovascular Quality and Outcomes, vol. 5, no. 6, pp. 819–829, 2012. View at: Publisher Site | Google Scholar
  71. W. B. Grant, “An estimate of the global reduction in mortality rates through doubling vitamin D levels,” European Journal of Clinical Nutrition, vol. 65, no. 9, pp. 1016–1026, 2011. View at: Publisher Site | Google Scholar
  72. N. Vilarrasa, J. Maravall, A. Estepa et al., “Low 25-hydroxyvitamin D concentrations in obese women: their clinical significance and relationship with anthropometric and body composition variables,” Journal of Endocrinological Investigation, vol. 30, no. 8, pp. 653–658, 2007. View at: Google Scholar

Copyright © 2014 Pawel Pludowski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.